Abstract
Residual Monoclonal Free Light Chain Positivity By Mass Spectrometry Identifies Patients at Increased Risk of Early Relapse Following First-Line Anti-Myeloma Treatment
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have